NTX-301

N/A

Report date: 2024/08/23 11:05:02
NME

Base Information

Drug NameNTX-301
Drug Alias Name5-aza-4'-thio-2'-deoxycytidineAza-TdCAza-T-dCydNTX-303
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA (cytosine-5)-methyltransferase 1 inhibitors
TargetsDNA (cytosine-5)-methyltransferase 1
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesOvarian Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSouthern Research InstitutePinotbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteUniversity Of Alabama At BirminghamPinotbio Inc
Inactive CompaniesXennials Therapeutics Australia Pty Ltd
Active IndicationsSolid tumoursMyelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic +[4] 
Inactive IndicationsOvarian NeoplasmsCarcinoma, Transitional CellGlioma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A